http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9616027-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6db915de580c9626b12c705a3ee6f2f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 |
| filingDate | 2014-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2217d1b7c4bab14a755f66f8d7cd871b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f84d853b2ba2bbb4bcd1229856875b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e816902fa4c5b532531dbf3d137a475b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4565d6e9a57dc2b68b7753617e67a93 |
| publicationDate | 2017-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9616027-B2 |
| titleOfInvention | Pramipexole sustained release tablet formulation and manufacturing method thereof and use thereof |
| abstract | The present invention relates to a method for preparing the sustained-release tablets via direct compression process, wet granulation process or dry granulation process to obtain the formulations. The present invention also provides a use of the sustained-release tablet formulation of pramipexole in the preparation of pharmaceutical compositions. A sustained release tablet formulation has advantages as follows: breaking out patent monopoly of the innovator preparation, drug dissolution release effects in vitro can be achieved and probably clinical treatment effects can also be accomplished consistent with that of the innovator preparation; abandoning anionic polymers used in the innovator preparation such that making the drug release and absorption not being influenced by the patent body's gastric pH values, in order to avoid the disadvantages of the innovator preparation. Once the tablet formulation is authorized to marketing, the price will be lowered, capable of bringing out effective medical treatment and economical spending for patients. |
| priorityDate | 2013-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.